Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Salmeterol MDI + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Salmeterol MDI + Placebo
Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Salmeterol MDI + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT00685841. Target conditions include COPD.
What happened to similar drugs?
20 of 20 similar drugs in COPD were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00685841 | Phase 3 | Completed |
Competing Products
20 competing products in COPD